NASDAQ$SNGX
Soligenix Inc · Q4 2026 earnings
Q4 2026 earnings · · Before market open
Briefing
Soligenix reported fiscal Q4 2026 with no revenue and a net loss of $2.8M as R&D spend declined.
For the three months ended March 31, 2026, Soligenix had no revenue and a net loss of $2.8 million versus $3.0 million a year ago. R&D expense was $1.8 million, down from $1.9 million, as Phase 3 CTCL trial costs moderated. Cash was $6.0 million at March 31, 2026.
- No revenue; clinical-stage biotech.
- Net loss $2.8M; R&D $1.8M.
- Cash $6.0M; going concern noted in filing.
- SGX301 Phase 3 program ongoing.
Headline financials
Revenue & EPS history
Soligenix Inc · Revenue · Quarterly
$119K
Forward guidance
ATM equity sales and grant funding support operations; 2026 revenue target for SGX301 trial not met creates substantial doubt.
Tailwinds
- R&D spend down YoY.
- Smaller net loss.
Headwinds
- Limited cash runway.
- Going concern uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2026
+0.8%
Avg return
Earnings day
+3.6%
Avg return
5 days after
+5.4%
Avg return
30 days after
47%
14 / 30 earnings
Positive
+20.0%
Q2 2025
Best reaction
-9.3%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.7% | +19.7% | +45.6% | |
| Q3 2025 | +7.0% | +6.3% | +25.8% | |
| Q2 2025 | +20.0% | +51.0% | +19.2% | |
| Q1 2025 | +0.5% | -3.6% | -2.0% | |
| Q3 2024 | +0.9% | +4.6% | -6.9% | |
| Q2 2024 | +0.0% | +1.6% | +19.1% | |
| Q1 2024 | -2.4% | -12.2% | -42.4% | |
| Q3 2023 | +0.0% | -4.8% | +40.5% | |
| Q2 2023 | +2.2% | +4.4% | +13.3% | |
| Q1 2023 | +6.4% | +0.0% | -5.1% | |
| Q3 2022 | +0.0% | -1.5% | -22.4% | |
| Q2 2022 | +2.3% | -1.1% | -20.7% | |
| Q1 2022 | -7.0% | +2.3% | +39.5% | |
| Q3 2021 | -1.1% | -2.2% | -17.4% | |
| Q2 2021 | +1.1% | +2.1% | +23.4% | |
| Q1 2021 | +5.6% | +16.9% | +36.0% | |
| Q3 2020 | +1.2% | +22.4% | +35.3% | |
| Q2 2020 | -1.9% | +3.9% | -8.2% | |
| Q1 2020 | +2.6% | +11.1% | +24.2% | |
| Q3 2019 | -5.7% | -11.3% | +17.0% | |
| Q2 2019 | -0.9% | -2.7% | -20.4% | |
| Q1 2019 | +2.8% | +2.8% | -2.8% | |
| Q3 2018 | -3.5% | -11.4% | -14.9% | |
| Q2 2018 | +5.0% | +2.9% | +5.0% | |
| Q1 2018 | +2.5% | +3.7% | -1.9% | |
| Q3 2017 | -1.0% | +5.9% | +0.0% | |
| Q2 2017 | -9.3% | -3.1% | -1.8% | |
| Q1 2017 | -0.4% | -3.1% | -15.3% | |
| Q3 2016 | +0.0% | +0.0% | -22.4% | |
| Q2 2016 | +0.0% | +3.2% | +24.2% | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro